Antipsychotic Drug Recalled for Failed Quality Control Test
Ascend Laboratories is recalling 135 bottles of Aripiprazole 20 mg tablets nationwide due to failure of spectroscopic identification testing, indicating the product may not meet established quality standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall of a prescription medication that failed critical identity testing (spectroscopic identification). While no illnesses or injuries have been reported, a drug that cannot be verified to meet identity specifications represents a risk-of-harm product, warranting a High severity rating.
Plain-English summary
Ascend Laboratories, LLC is recalling 135 bottles of Aripiprazole 20 mg tablets distributed nationwide. The recall was initiated because the product failed spectroscopic identification testing by infrared (IR) analysis, meaning the tablets do not meet established quality and identity specifications.
Aripiprazole is a prescription antipsychotic medication. When a drug fails identity testing, it indicates uncertainty about the product's chemical composition and purity, raising concerns about whether the medication is correctly formulated and safe to use.
The affected lot is #22143120 with an expiration date of June 2024. If you have Aripiprazole tablets from this lot, do not use them. Contact your pharmacy or healthcare provider immediately for guidance on obtaining a replacement prescription.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Antipsychotic
- Hazard
- out-of-specification
- quality-control-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #22143120
- Exp. Date: June 2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27